Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study.

OBJECTIVES The aim of this study was to investigate the importance of aPL type and level for non-criteria-related events in APS patients. METHODS Our study included 374 patients: 260 with PAPS and 114 with APS associated with systemic lupus erythematosus (SLE). RESULTS We discovered significant connection between migraine and LA absence, livedo reticularis and aCL-IgG, skin ulcerations with aCL-IgG and anti-β2GPI-IgM, pseudovasculitis lesions with aCL-IgG, aCL-IgM and anti-β2GPI-IgM, and thrombocytopenia with aCL-IgM, aCL-IgG and anti-β2GPI-IgG. Thrombocytopenia occurred more frequently in patients with more than one aPL. In PAPS, epilepsy correlated with ß2GPI-IgM, migraine with aCL-IgM, and thrombocytopenia with aCL-IgM, aCL-IgG, anti ß2GPI-IgG and LA. Skin ulcerations occurred more frequently in IIc category patients and in patients with high levels of aCL-IgG and anti ß2GPI-IgG. Livedo reticularis was more prominent in PAPS with high levels of aCL-IgG. Significantly higher prevalence of thrombocytopenia was observed in patients with high levels of aCL-IgG and anti ß2GPI-IgG. Epilepsy was related to high levels of anti ß2GPI-IgM and thrombocytopenia in the SAPS was correlated with aCL-IgG. Skin ulcerations were more prevalent in aCL-IgM positive SAPS patients and epilepsy more frequently in SAPS patients with high levels of anti ß2GPI-IgG. CONCLUSIONS Our study showed that certain aPL type with certain level correlated with non-criteria manifestations, suggesting their predictive role.

[1]  E. Peeva,et al.  B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data. , 2012, Autoimmunity reviews.

[2]  R. Cervera,et al.  Does seronegative antiphospholipid syndrome really exist? , 2012, Autoimmunity reviews.

[3]  M. Tomšič,et al.  Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome. , 2011, Clinical and experimental rheumatology.

[4]  A. Triantafyllou,et al.  Association of capillaroscopic microhaemorrhages with clinical and immunological antiphospholipid syndrome. , 2011, Clinical and experimental rheumatology.

[5]  M. Barbhaiya,et al.  Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-β2-glycoprotein-I antibody positivity offer additional predictive information? , 2010, Lupus.

[6]  P. Meroni,et al.  The geoepidemiology of the antiphospholipid antibody syndrome. , 2010, Autoimmunity reviews.

[7]  Y. Shoenfeld,et al.  The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. , 2009, Journal of autoimmunity.

[8]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[9]  P. Szodoray,et al.  Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. , 2008, Rheumatology.

[10]  K. Moder,et al.  Antiphospholipid Antibody-Associated Chorea , 2008, The Journal of Rheumatology.

[11]  Y. Shoenfeld,et al.  Amputation of digits or limbs in patients with antiphospholipid syndrome. , 2008, Seminars in arthritis and rheumatism.

[12]  A. Tincani,et al.  Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. , 2008, Rheumatology.

[13]  P. Meroni.  Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. , 2008, Journal of autoimmunity.

[14]  L. Stojanovich,et al.  Ocular manifestations in antiphospholipid syndrome. , 2007, Autoimmunity reviews.

[15]  G. Zandman-Goddard,et al.  Psychiatric manifestations in systemic lupus erythematosus. , 2007, Autoimmunity reviews.

[16]  J. Chapman,et al.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. , 2007, Seminars in arthritis and rheumatism.

[17]  S. D. De Luka,et al.  Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases , 2007, Lupus.

[18]  M. Matsumoto.  [Classification of cerebrovascular diseases in Japan and other countries: historical changes and future perspective]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[19]  Y. Shoenfeld,et al.  Autoimmune Hemolytic Anaemia in the Antiphospholipid Syndrome , 2006, Lupus.

[20]  L. Stojanovich.  Pulmonary manifestations in antiphospholipid syndrome. , 2006, Autoimmunity reviews.

[21]  V. Pascual,et al.  Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome. , 2006, Journal of autoimmunity.

[22]  Y. Shoenfeld,et al.  The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. , 2005, Immunobiology.

[23]  G. Hughes,et al.  Prevalence of the antiphospholipid syndrome in primary systemic vasculitis , 2005, Annals of the rheumatic diseases.

[24]  G. Hughes,et al.  Diagnosis of antiphospholipid syndrome , 2005, Nature Clinical Practice Rheumatology.

[25]  Y. Shoenfeld,et al.  Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. , 2005, Clinical and Experimental Rheumatology.

[26]  I. Uthman,et al.  Ethnic and geographical variation in antiphospholipid (Hughes) syndrome , 2005, Annals of the rheumatic diseases.

[27]  S. Iliceto,et al.  Antibody profiles for the diagnosis of antiphospholipid syndrome , 2005, Thrombosis and Haemostasis.

[28]  G. Hughes,et al.  Antiphospholipid antibody tests: spreading the net , 2005, Annals of the rheumatic diseases.

[29]  J. Chapman,et al.  Close association between valvular heart disease and central nervous system manifestations in antiphospholipid syndrome , 2005, Arthritis Research & Therapy.

[30]  M. García-Carrasco,et al.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients , 2004, Annals of the rheumatic diseases.

[31]  R. Cervera,et al.  Unusual manifestations of the antiphospholipid syndrome , 2003, Clinical reviews in allergy & immunology.

[32]  R. Levine,et al.  Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[33]  G. Hughes,et al.  Central nervous system involvement in the antiphospholipid (Hughes) syndrome. , 2003, Rheumatology.

[34]  R. Benedict,et al.  Chorea and rapidly progressive subcortical dementia in antiphospholipid syndrome. , 2002, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[35]  Y. Shoenfeld,et al.  [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population]. , 2001, Harefuah.

[36]  S. Pierangeli,et al.  'Equivocal' antiphospholipid syndrome. , 2000, Journal of autoimmunity.

[37]  R. Brey.  Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome. , 2000, Journal of autoimmunity.

[38]  J. Piette,et al.  The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. , 2000, Journal of autoimmunity.

[39]  P. Fiallo,et al.  Antibodies to Beta2-Glycoprotein I in Ischemic Stroke , 2000, Cerebrovascular Diseases.

[40]  J. Piette,et al.  Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. , 1999, Medicine.

[41]  S. Paira,et al.  Extensive cutaneous necrosis associated with anticardiolipin antibodies. , 1999, Journal of Rheumatology.

[42]  J. Piette,et al.  Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome , 1997, British journal of haematology.

[43]  G. Hughes,et al.  Thrombocytopenia in the antiphospholipid syndrome , 1997, Medicina clinica.

[44]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[45]  G. Hughes.  The antiphospholipid syndrome: ten years on , 1993, The Lancet.

[46]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[47]  Robert A. Zimmerman,et al.  Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. , 1990, Stroke.

[48]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[49]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[50]  M. Lockshin,et al.  61 – Antiphospholipid syndrome , 2008 .

[51]  Y. Shoenfeld,et al.  The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008. , 2008, The Israel Medical Association journal : IMAJ.

[52]  J. Piette,et al.  The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. , 2006, Clinical and experimental rheumatology.

[53]  J. Vianna,et al.  Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. , 1994, The American journal of medicine.